Delving into the Latest Updates on Desoximetasone with Synapse

Psoriasis and atopic dermatitis are chronic inflammatory disease that account for a significant amount of patients in most dermatological practices. Topical corticosteroid agents are often prescribed for treatment of both these conditions, especially when they are localized rather than wide spread. The development of resistance to treatment is termed tachyphylaxis. Poor adherence, rather than down regulation of receptors, may be the primary cause of tachyphylaxis to topical corticosteroids. The primary objective of the study is to determine, under conditions designed to assure good adherence, whether topical 0.25% desoximetasone spray improves clinical outcomes in patients who have resistant inflammatory skin disease defined by failure of previous topical steroid treatment.

Start Date01 Feb 2017

Sponsor / Collaborator

Wake Forest School of Medicine

100 Clinical Results associated with Desoximetasone

Login to view more data

100 Translational Medicine associated with Desoximetasone

Login to view more data

100 Patents (Medical) associated with Desoximetasone

Login to view more data

171

Literatures (Medical) associated with Desoximetasone

01 Nov 2025·OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY

Risk Factors for Worsening Dry Eye Symptoms in Patients Undergoing External Levator Advancement Surgery

Article

Author: Christine J. Zemsky ; Marycon C. Jiro ; Noam Rudnick ; Larissa K. Ghadiali ; Bryan J. Winn

Purpose::

Few studies have examined dry eye syndrome (DES) as a consequence of external levator advancement surgery. The purpose of this retrospective study was to examine risk factors for dry eye signs and symptoms after external levator advancement in order to improve preoperative planning.

Methods::

A retrospective chart analysis was performed on all patients who underwent external levator advancement from January 2010 to April 2015 performed by one surgeon (B.J.W.). Margin reflex distance-1 (MRD1) and margin reflex distance-2 were measured preoperatively and postoperatively. Dry eye symptoms (DSXs) were recorded for visits preoperatively, postoperatively at week 1, and postoperatively at month 3. DSXs were graded 0 to 3. Subgroup analysis was performed on patients with pre-existing DES diagnosis and on eyes undergoing additional simultaneous procedures. Statistical measures included linear regression, Pearson χ 2 tests, and analysis of variance with post hoc comparison tests.

Results::

A total of 190 eyes (115 patients) were included; 39% were patients with DES and 56% had simultaneous surgeries. Postoperative values for both MRD1 and margin reflex distance-2 and the change in values for MRD1 (postoperatively at month 3 to preoperatively) were statistically significant between patients with worsening versus those without worsening DSX. Differences in DSX in patients with DES were significant preoperatively and postoperatively at week 1 but not postoperatively at month 3. Comparing those patients with DES with worsening DSX versus those with improving DSX, those with worsening DSX had no difference in final MRD1 but did have a greater change in MRD1.

Conclusions::

Larger postoperative values of MRD1, margin reflex distance-2, and change in MRD1 are associated with worsening postoperative dry eye symptoms in those undergoing external levator advancement. In patients with DES, there was no significant difference in final MRD1; however, a greater change from preoperative and postoperative MRD1 was associated with worsening DSX. Oculoplastic surgeons may consider doing simultaneous lower eyelid surgery that decreases margin reflex distance-2 to potentially help reduce the chance of postoperative dry eye symptoms.

01 May 2025·BIOMEDICINE & PHARMACOTHERAPY

Sakuranetin modulates IL-17A-related inflammation and enhances skin barrier function in an imiquimod-induced psoriasis model

Article

Author: Chen, Yung-Chuan ; Lai, Chien-Yu ; Wang, Tzu-Ming ; Guo, Jiun-Wen ; Wang, Wei-Chin ; Liu, Chih-Yi ; Cheng, Yu-Ping

Sakuranetin, a methoxylated flavanone with known anti-inflammatory and antioxidant properties, has yet to be explored for its therapeutic potential in psoriasis treatment. This study evaluates its efficacy in an imiquimod-induced psoriasis-like murine model, focusing on both immune modulation and skin barrier restoration. Topical administration of sakuranetin significantly attenuated psoriatic inflammation, with high-dose treatment achieving comparable efficacy to desoximetasone. RNA sequencing and qPCR validation revealed that sakuranetin modulates keratinization, cornified envelope formation, and kallikrein-related peptidase activity, suggesting its role in epidermal homeostasis. Notably, sakuranetin selectively downregulated IL-17A while maintaining IL-17F expression, supporting a targeted immunomodulatory effect. Additionally, sakuranetin upregulated KRT1, KRT16, KLK7, Sprr2f, and Wfdc18 while downregulating Sprr2k and Sprr3, indicating a refined regulation of skin barrier proteins. The observed upregulation of Tslp suggests a potential role in epidermal repair mechanisms. These findings highlight sakuranetin as a novel, plant-derived therapeutic candidate with dual anti-inflammatory and skin barrier-enhancing properties, providing a potential corticosteroid-sparing approach for long-term psoriasis management.

01 Apr 2025·FOOD CHEMISTRY

Unbiased Metabolomic and Chemometric profiles of three Sargassum polycystum extracts using GCMS and LCMS/MS: content analysis, correlation analysis and molecular docking

Article

Author: Alallam, Batoul ; Abdulameed, Hassan Taiye ; Lim, Vuanghao

Sargassum polycystum (S. polycystum) is a brown macroalga with a high phytochemical content, making it a nutritious and bioactive food source. However, information on factors contributing to health benefits, like antioxidants and cytotoxicity, is less explored for Malaysian S. polycystum. In this study, three extracts of S. polycystum were characterized using a combination of analytical techniques. Despite similar carbohydrate content across all extracts, water extract exhibited the highest protein [21.90 ± 1.01 albumin equivalent (μg/mg)] and phenolic [7.73 ± 1.95 gallic acid equivalent (μg/mg)] contents. However, it displayed the lowest antioxidant and anticancer activities [half-maximal inhibitory concentration (IC₅₀) of > 2000 μg/mL]. Interestingly, ethanolic extract demonstrated the strongest scavenging activity (IC₅₀ of 397.90 ± 20.43 μg/mL) and selective anticancer activity against MCF7 breast cancer cells (IC₅₀ of 338.63 ± 48.98 μg/mL). Untargeted metabolomic profiling confirmed the differences in the chemical composition of the extracts. Subsequently, correlation and docking analyses were used to identify the potential bioactive compounds within the extracts. The ethanolic extract is a rich source of these bioactive compounds with superior antioxidant and anticancer properties, highlighting the need for further research on its potential utility in the food industry.

1

News (Medical) associated with Desoximetasone

16 Jun 2026

·www.biospace.com

Saptalis Pharmaceuticals Launches Cyclosporine Ophthalmic Emulsion 0.05% and Expands Product Portfolio

HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Saptalis Pharmaceuticals LLC today announced the commercial launch of Cyclosporine Ophthalmic Emulsion 0.05% , available in 30- and 60-count single-use vials, reinforcing its commitment to expanding access to high-quality treatments. Dry eye disease affects millions of patients worldwide. Cyclosporine Ophthalmic Emulsion 0.05% is a preservative-free, single-use formulation indicated to increase tear production and provides a convenient option for managing inflammation-associated tear deficiency. In addition to Cyclosporine Ophthalmic Emulsion, Saptalis also announced the approval and launch of several other products across multiple therapeutic categories: Tofacitinib Oral Solution, 1 mg/mL (240 mL) : Indicated for the treatment of autoimmune and inflammatory conditions, including rheumatoid arthritis and related disorders. Hydroxyzine HCl Oral Solution, USP 10 mg/5 mL (473 mL) : Indicated for the symptomatic relief of anxiety and tension, and for the management of pruritus due to allergic conditions. Chlorpromazine HCl Oral Concentrate, 30 mg/mL (120 mL) and 100 mg/mL (240 mL) : Indicated for the treatment of schizophrenia, psychotic disorders, and for the control of severe nausea and vomiting. Desoximetasone Cream, USP 0.05% and 0.25% (15 g and 60 g) : Indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Fluocinonide Topical Solution, USP 0.05% (20 mL and 60 mL) : Indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive scalp and skin conditions. “With these launches, we continue to grow our generic business segment with U.S.-based manufacturing, while maintaining our primary focus on advancing our pipeline of innovative branded therapies addressing unmet medical needs,” said Polireddy Dondeti, President and CEO of Saptalis Pharmaceuticals LLC. These additions strengthen Saptalis’ portfolio of liquid and semi-solid dosage forms across ophthalmology, dermatology, psychiatry, and allergy-related therapeutic areas. All products are available by prescription and should be used under the supervision of a licensed healthcare provider. For full prescribing information, please visit or contact info@saptalis.com . About Saptalis Pharmaceuticals Saptalis Pharmaceuticals LLC is a specialty pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of generic and specialty brand products, with a focus on liquid and semi-solid dosage forms. Headquartered in Hauppauge, New York, Saptalis operates R&D laboratories and a commercial manufacturing facility compliant with U.S. FDA cGMP standards. Website: Contacts Peruvemba Satish Chief Financial Officer and Chief Commercial Officer (631) 231-2751 info@saptalis.com

Drug Approval

100 Deals associated with Desoximetasone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03697	Desoximetasone	D07AC03 D07XC02	DB00547

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Plaque psoriasis	United States	Sun Pharma Canada, Inc.	11 Apr 2013
Dermatophilosis	United States	Taro Pharmaceutical Industries Ltd.	17 Jan 1985
Skin Diseases	United States	Taro Pharmaceutical Industries Ltd.	28 Feb 1977

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psoriasis of scalp	Phase 3	United States	Taro Pharmaceuticals U.S.A., Inc.	11 Mar 2016
Moderate Atopic Dermatitis	Phase 3	United States	Taro Pharmaceuticals U.S.A., Inc.	04 Sep 2015
Severe Atopic Dermatitis	Phase 3	United States	Taro Pharmaceuticals U.S.A., Inc.	04 Sep 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02985736 (CTgov)	Phase 4	Psoriasis of scalp	20	Topicort	qnpzelbfvp(rbdpwiwmlz) = swyegtyhbj ugvhdwpyig (usjtbkhwal, vmdektxdfp - ajnrkjormb) View more	-	09 Apr 2024
NCT02618759 (CTgov)	Phase 3	Plaque psoriasis	119	Placebo+DSXS (DSXS1505)	nlxahqqjrr = tuvqvyyxvx ijtriachwk (bucuxyhxmo, pztkwezbqy - cadmuqccxk) View more	-	10 Dec 2018
				Placebo+DSXS (Placebo)	nlxahqqjrr = jxvrwquizm ijtriachwk (bucuxyhxmo, izdbmrktls - bhyckpnjvt) View more
NCT02595073 (CTgov)	Phase 3	Moderate Atopic Dermatitis \| Severe Atopic Dermatitis	124	DSXS (DSXS Topical Product)	snujjbabnh = pzuafyquln cnlnaxdyhc (ozdodndkid, iekbsanmvg - jrxlbwatkv) View more	-	07 Dec 2018
				Placebo (Placebo Topical Product)	snujjbabnh = fgjwcreqdd cnlnaxdyhc (ozdodndkid, sfawngiukx - itihztqbsm) View more
NCT02595008 (CTgov)	Phase 2	Dermatitis, Atopic	24	DSXS (DSXS Topical Product Cohort 1)	okjmpyfyjk = gmfpdxqjqi zakvnljido (lcctdezcvk, yffrbfyfrb - shrlunzmla) View more	-	07 Dec 2018
				DSXS (DSXS Topical Product Cohort 2)	okjmpyfyjk = tignqdjytn zakvnljido (lcctdezcvk, rkmybxvcpp - gsvucqatkt) View more
NCT02601469 (CTgov)	Phase 2	Plaque psoriasis	26	DSXS (DSXS1503 Cohort 1)	qcvbqthnuu = rxuhkocrgi pywqzpbpkc (pzjanqrleq, vjolttqxad - ixthiurvac) View more	-	07 Dec 2018
				DSXS (DSXS1503 Cohort 2)	qcvbqthnuu = rvxmpnswee pywqzpbpkc (pzjanqrleq, zlgcpoqixv - twrejzdbav) View more
NCT02932891 (CTgov)	Phase 2	Dermatitis, Atopic	28	DSXS	mxfzwadujr = nvkrqbsgzo crprfaakik (wmpvtorhct, ltysgiyttj - sepyktibxp) View more	-	07 Dec 2018
NCT02933528 (CTgov)	Phase 2	Psoriasis of scalp	24	DSXS Topical product	fpqtejvnjl = tmksgznkvt qlqwnalyrf (pyvbtkjvvk, ojnhqabwrn - iecvavsetn) View more	-	06 Dec 2018
NCT02932878 (CTgov)	Phase 2	Plaque psoriasis	16	DSXS (DSXS Topical Cohort 1)	wghtwkchzy = bjadmsiwer etjenhwtfw (udstgkiaal, lcmtxvrljq - coudxjvmhx) View more	-	06 Dec 2018
				DSXS (DSXS Topical Cohort 2)	wghtwkchzy = vjxtwiyutx etjenhwtfw (udstgkiaal, yxetivztab - ggotdcouai) View more
NCT02933866 (CTgov)	Phase 3	Psoriasis of scalp	371	DSXS topical (DSXS Topical)	hhlrrbvyoe = ysfqwuhusb bckqbhqhav (jrzplqsubm, iueqamsltf - kjwlqsblsl) View more	-	06 Dec 2018
				Vehicle topical (Vehicle Topical)	hhlrrbvyoe = pverxyydsj bckqbhqhav (jrzplqsubm, ooddfdnchf - qidedcjgkb) View more
NCT03050294 (CTgov)	Phase 4	Plaque psoriasis \| Psoriasis \| Dermatitis, Atopic	24	Desoximetasone 0.25% spray (Control- Atopic Dermatitis)	mgeystbwnk(cwerkolxst) = thvpjjuklm nybyvplwma (kmvzfckgje, 0.8) View more	-	15 Jun 2018
				Phone calls+Desoximetasone 0.25% spray (Atopic Dermatitis Intervention)	mgeystbwnk(cwerkolxst) = gienjnaaoi nybyvplwma (kmvzfckgje, 1.4) View more